Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- PR-15
- DrugBank Accession Number
- DB06037
- Background
PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- GPVI-Fc
- Revacept
Pharmacology
- Indication
Investigated for use/treatment in atherosclerosis and thrombosis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
PR-15 is a lesion-specific platelet adhesion inhibitor. It is a soluble glycoprotein IV (GPVI) receptor found on platelets. It binds selectively to exposed collagen, and prevents GPVI-mediated platelet adhesion and activation that triggers thrombosis and atherosclerosis.
Target Actions Organism UCollagen alpha-1(I) chain Not Available Humans UCollagen alpha-2(I) chain Not Available Humans UCollagen alpha-1(III) chain Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Groschel K, Uphaus T, Loftus I, Poppert H, Diener HC, Zobel J, Munch G: Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Artery Stenosis: Design and Rationale of a Randomized Phase II Clinical Trial. TH Open. 2020 Nov 30;4(4):e393-e399. doi: 10.1055/s-0040-1721078. eCollection 2020 Oct. [Article]
- Ungerer M, Li Z, Baumgartner C, Goebel S, Vogelmann J, Holthoff HP, Gawaz M, Munch G: The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times. PLoS One. 2013 Aug 12;8(8):e71193. doi: 10.1371/journal.pone.0071193. eCollection 2013. [Article]
- External Links
- Wikipedia
- Puerto_Rico_Highway_15
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Treatment Amaurosis Fugax / Atherosclerosis / Stenosis, Carotid / Stroke / Transient Ischemic Attack 1 somestatus stop reason just information to hide 2 Completed Treatment Stable Coronary Artery Disease (CAD) 1 somestatus stop reason just information to hide 1 Completed Treatment Acute Coronary Syndrome (ACS) / Myocardial Infarction / Stroke / Thrombosis 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Type I collagen is a member of group I collagen (fibrillar forming collagen)
- Specific Function
- Extracellular matrix structural constituent conferring tensile strength
- Gene Name
- COL1A1
- Uniprot ID
- P02452
- Uniprot Name
- Collagen alpha-1(I) chain
- Molecular Weight
- 138911.075 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Type I collagen is a member of group I collagen (fibrillar forming collagen)
- Specific Function
- Extracellular matrix structural constituent
- Gene Name
- COL1A2
- Uniprot ID
- P08123
- Uniprot Name
- Collagen alpha-2(I) chain
- Molecular Weight
- 129313.615 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Collagen type III occurs in most soft connective tissues along with type I collagen. Involved in regulation of cortical development. Is the major ligand of ADGRG1 in the developing brain and binding to ADGRG1 inhibits neuronal migration and activates the RhoA pathway by coupling ADGRG1 to GNA13 and possibly GNA12
- Specific Function
- Extracellular matrix structural constituent
- Gene Name
- COL3A1
- Uniprot ID
- P02461
- Uniprot Name
- Collagen alpha-1(III) chain
- Molecular Weight
- 138564.005 Da
Drug created at November 18, 2007 18:29 / Updated at July 24, 2024 23:35